Boris Medvedovsky
Internal Medicine · Sarasota, FLNPI 1689833303
Payments from drug & device makers
Across 62 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$216
- Medtronic$127
- Pfizer$110
- Novo Nordisk$107
- Novartis$98
- Teva Pharmaceuticals USA, Inc.$97
- plus $703 from 21 others
What the payments were for
- Food & beverage$1,43999%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 6 | $216 |
| Medtronic | 1 | $127 |
| Pfizer | 6 | $110 |
| Novo Nordisk | 5 | $107 |
| Novartis | 5 | $98 |
| Teva Pharmaceuticals USA, Inc. | 3 | $97 |
| Amgen | 5 | $91 |
| Dexcom, Inc. | 3 | $67 |
| Sumitomo Pharma America, Inc. | 3 | $66 |
| Lilly USA, LLC | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| AbbVie | 2 | $42 |
| AstraZeneca | 2 | $35 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| GE HealthCare | 1 | $26 |
| Exact Sciences | 1 | $24 |
| Shield Therapeutics Inc | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Akebia Therapeutics Inc | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$127
- Kerendia$123
How this compares
$1,458 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $29,675 |
| LinzessLinaclotide | 37 | $26,160 |
| MounjaroTirzepatide | 13 | $13,673 |
| EliquisApixaban | 15 | $9,467 |
| JardianceEmpagliflozin | 12 | $9,391 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,287 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,440 |
| GemtesaVibegron | 14 | $8,254 |
| MyrbetriqMirabegron | 12 | $7,894 |
| Repatha SureclickEvolocumab | 14 | $7,811 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,095 |
| MovantikNaloxegol Oxalate | 14 | $3,334 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,839 |
| Nifedipine ErNifedipine | 12 | $1,759 |
| Ventolin HfaAlbuterol Sulfate | 13 | $809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $107 | $29,67531 claims |
| AbbVieLinzess | $42 | $26,16037 claims |
| Lilly USA, LLCMounjaro | $59 | $13,67313 claims |
| GSKTrelegy Ellipta, Shingrix | $19 | $12,12625 claims |
| PfizerEliquis | $110 | $9,46715 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $66 | $8,25414 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $7,89412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Sarasota
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.